AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

Analyst Ratings

Consensus Ratings for AMAG Pharmaceuticals (NASDAQ:AMAG) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $39.33 (57.65% upside)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannLower Price TargetOutperform$45.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016GuggenheimLower Price TargetBuy$54.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2016Barclays PLCInitiated CoverageEqual Weight$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2015Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015FBR & CoReiterated RatingMarket Perform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$1.21$1.02$113.88 million$103.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2015Q414$0.30$0.06$52.69 million$53.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012($0.39)$0.16ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.13$0.68$0.36
Q2 20163$0.14$0.76$0.54
Q3 20165$0.22$0.90$0.53
Q4 20163$0.60$1.06$0.89
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateHeadline
07/25/16 08:30 PMAMAG Pharmaceuticals Inc. to report financial results
07/25/16 02:59 PMAMAG Pharmaceuticals (AMAG) Shares are Up 1.02% - Trade Calls
07/23/16 06:40 AMAMAG Pharmaceuticals Inc. to report financial results - MetroWest Daily News
07/22/16 07:28 PMWorst Performing Industries For July 22, 2016 - Benzinga
07/22/16 02:26 PMWhat's in AMAG Pharmaceuticals, Inc. After Today's Huge Decline? - Consumer Eagle
07/22/16 11:43 AMWorst Performing Industries For July 22, 2016 - The Dow fell 0.01 percent to 18,514.66, while the NASDAQ composite index climbed 0.26 percent to 5,087.20. The broader Standard & Poor's 500 index gained 0.16 percent to 2,168.57. The worst performing industries in the market today are: Diagnostic Substances: This industry slipped 1.2 percent by 11:00 am. The worst stock within the industry was AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), which ...Full story available on Benzinga.com
07/22/16 10:37 AMTwo Buzzers within Analysts Radar: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , AMAG Pharmaceuticals, Inc ... - Street Updates
07/22/16 05:03 AMAMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events -
07/21/16 02:26 PMAMAG Pharmaceuticals to Host Conference Call on August 9, 2016 at 8:00 a.m. ET to Discuss Financial Results for the ... - Nasdaq
07/21/16 10:38 AMTracking Analyst Ratings and Target Projections for: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph
07/21/16 10:38 AMEarnings Focus and Crowd Sourced Sentiment Review for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - TGP
07/21/16 10:38 AMCurrent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) PT Means Stock Is Worth Almost $58 - Review Fortune
07/21/16 07:00 AMAMAG Pharmaceuticals to Host Conference Call on August 9, 2016 at 8:00 a.m. ET to Discuss Financial Results for the Second Quarter Ended June 30, 2016 - [GlobeNewswire] - WALTHAM, Mass., July 21, 2016-- AMAG Pharmaceuticals, Inc. today announced it will report unaudited consolidated financial results for the second quarter ended June 30, 2016 before the U.S. financial markets ...
07/19/16 07:53 PMAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 02:26 PMAmag Pharmaceuticals Incorporated (NASDAQ:AMAG) Shorted Shares Increased 6.53% After Market Selling - Press Telegraph
07/19/16 02:26 PMAMAG Pharmaceuticals Inc Realized Volatility Hits a Dropping Level - CML News
07/19/16 08:39 AMTeva Pharmaceutical Industries Ltd (NYSE:TEVA) Joins Pharmaceutical Research And Manufacturers Of America ... - Market Exclusive
07/18/16 02:30 PMBRIEF-AMAG Pharmaceuticals CEO William Heiden elected to PhRMA board - Reuters
07/18/16 02:30 PMShare Performance Summary for: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph
07/18/16 07:16 AMTrading Performance and Target Watch for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph
07/18/16 07:16 AMShares of AMAG Pharmaceuticals (AMAG) Rally 1.67% - Trade Calls
07/18/16 07:16 AMAMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors - GlobeNewswire (press release)
07/18/16 07:00 AMAMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors - [GlobeNewswire] - WALTHAM, Mass., July 18, 2016-- AMAG Pharmaceuticals, Inc. today announced that William Heiden, chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers ...
07/16/16 10:51 AMFive new member companies, Alexion, Jazz, Teva, AMAG and Horizon join with PhRMA
07/14/16 02:30 PMCrowd Rating and Earnings Recap for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Telanagana Press
07/13/16 07:57 PMAnalyst Target and Average Rating Watch: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph
07/13/16 07:57 PMAMAG Pharmaceuticals Inc versus Ironwood Pharmaceuticals Inc Head to Head Compare - CML News
07/13/16 02:28 PMShares Turning Downward: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Telanagana Press
07/13/16 02:28 PMNew Broker Ratings For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - FTSE News
07/13/16 02:28 PMAMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts - Yahoo Finance
07/13/16 02:28 PMAnalysts Observable Stocks: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) , AMAG Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/13/16 02:28 PMAMAG Pharmaceuticals announces new VP - MetroWest Daily News
07/13/16 10:30 AMAMAG Pharmaceuticals announces new VP
07/12/16 07:55 PMAMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts - Investing News Network (press release) (registration) (blog)
07/12/16 02:29 PMAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 02:29 PMAMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts - GlobeNewswire (press release)
07/12/16 07:31 AMAMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts - Nasdaq
07/12/16 07:13 AMAMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts - [at noodls] - WALTHAM, Mass., July 12, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Mark Stanton to the newly created position of vice president, market access ...
07/11/16 07:14 AMStock on the Rise for the Quarter: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Engelwood Daily
07/11/16 07:14 AMStock Performance Rundown on: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph
07/10/16 07:12 AMAre Analysts Bearish AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) After Last Week? - Engelwood Daily
07/09/16 02:24 PMAmag Pharmaceuticals Incorporated (NASDAQ:AMAG) Short Interest Decreased By 3.07% - Engelwood Daily
07/08/16 02:26 PMWall Street Ratings and Target Price Views on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Telanagana Press
07/07/16 02:27 PMShares Declining and Worrying Investors: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Telanagana Press
07/07/16 10:25 AMIntravenous (IV) Iron Drugs Market : Current Trends, Issues, Challenges and Outlook 2014 to 2020
07/06/16 02:30 PMBroker Outlook For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Fiscal Standard
07/06/16 07:14 AMShares Providing Results This Month for Investors: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Telanagana Press
07/05/16 02:24 PMAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Stock Rating Update - Investor Newswire
07/04/16 02:25 PMAmag Pharmaceuticals Incorporated (NASDAQ:AMAG) Shorts Decreased by 3.07% After Short Covering - Engelwood Daily
07/04/16 02:25 PMShare Performance Recap for: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Press Telegraph

Social

About AMAG Pharmaceuticals

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMAG
  • CUSIP: 00163U10
Key Metrics:
  • Previous Close: $24.95
  • 50 Day Moving Average: $24.25
  • 200 Day Moving Average: $23.48
  • P/E Ratio: 83.44
  • P/E Growth: -2.63
  • Market Cap: $862.72M
  • Beta: 0.61
  • Current Year EPS Consensus Estimate: $1.43 EPS
  • Next Year EPS Consensus Estimate: $3.29 EPS
Additional Links:
AMAG Pharmaceuticals (NASDAQ:AMAG) Chart for Wednesday, July, 27, 2016